Investor updates Suchbegriff Suchen Löschen 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 22 Mai 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use mehr Published on: 22 Mai 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder mehr Published on: 19 Mai 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer mehr Published on: 15 Mai 2020 Roche launches new blood gas digital solution designed to improve patient care mehr Published on: 14 Mai 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO mehr Published on: 11 Mai 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 mehr Published on: 11 Mai 2020 Wechsel in der erweiterten Konzernleitung von Roche mehr Published on: 7 Mai 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care mehr Published on: 6 Mai 2020 Invitation to Roche’s virtual event on key oncology data presented at ASCO 2020 mehr Published on: 3 Mai 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr Published on: 30 April 2020 Reminder: Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis mehr Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) mehr Published on: 24 April 2020 Positive Results from the Phase III SAkuraStar Study for Satralizumab in NMOSD Published in The Lancet Neurology mehr Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates mehr Published on: 21 April 2020 Reminder: Invitation to Roche’s live audio webcast on new AAN 2020 data mehr Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer mehr Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time mehr Published on: 17 April 2020 Roche develops new serology test to detect COVID-19 antibodies mehr Published on: 15 April 2020 Reminder: Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr Published on: 8 April 2020 Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan mehr Published on: 8 April 2020 Invitation to Roche’s live audio webcast on new AAN 2020 data mehr Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) mehr Published on: 7 April 2020 Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr Published on: 27 März 2020 FDA accepts Roche’s New Drug Application for Xofluza (baloxavir marboxil) for the treatment of influenza in children mehr Published on: 25 März 2020 Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr Published on: 24 März 2020 Roche response to COVID-19 pandemic mehr Published on: 23 März 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia mehr Published on: 19 März 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia mehr Published on: 17 März 2020 Roche Annual General Meeting 2020 mehr Published on: 16 März 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance mehr Published on: 14 März 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended mehr Published on: 13 März 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr Published on: 12 März 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia mehr Published on: 11 März 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention mehr Published on: 4 März 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma mehr Published on: 3 März 2020 FDA grants Breakthrough Therapy Designation for Roche’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease mehr Published on: 25 Februar 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer mehr Published on: 21 Februar 2020 Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer mehr Published on: 19 Februar 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer mehr Published on: 14 Februar 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer mehr Published on: 11 Februar 2020 Reminder: Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr Published on: 10 Februar 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease mehr Published on: 7 Februar 2020 Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer mehr Published on: 6 Februar 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy mehr Published on: 31 Januar 2020 Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia mehr Published on: 31 Januar 2020 Reminder: Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr Published on: 30 Januar 2020 Roche reports very strong results in 2019 mehr Published on: 27 Januar 2020 Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr Published on: 27 Januar 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer mehr Published on: 24 Januar 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer mehr Published on: 23 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr Published on: 23 Januar 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy mehr Published on: 21 Januar 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma mehr Published on: 17 Januar 2020 Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr Published on: 13 Januar 2020 Roche and Illumina partner to broaden patient access to genomic testing mehr Published on: 10 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr Published on: 2 Januar 2020 F1CDx approved in Japan as a CDx of ROS1+NSCLC for Rozlytrek mehr
Published on: 22 Mai 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use mehr
Published on: 22 Mai 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder mehr
Published on: 19 Mai 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer mehr
Published on: 15 Mai 2020 Roche launches new blood gas digital solution designed to improve patient care mehr
Published on: 14 Mai 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO mehr
Published on: 11 Mai 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 mehr
Published on: 7 Mai 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care mehr
Published on: 6 Mai 2020 Invitation to Roche’s virtual event on key oncology data presented at ASCO 2020 mehr
Published on: 3 Mai 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr
Published on: 30 April 2020 Reminder: Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr
Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis mehr
Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) mehr
Published on: 24 April 2020 Positive Results from the Phase III SAkuraStar Study for Satralizumab in NMOSD Published in The Lancet Neurology mehr
Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates mehr
Published on: 21 April 2020 Reminder: Invitation to Roche’s live audio webcast on new AAN 2020 data mehr
Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer mehr
Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time mehr
Published on: 15 April 2020 Reminder: Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr
Published on: 8 April 2020 Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan mehr
Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) mehr
Published on: 7 April 2020 Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr
Published on: 27 März 2020 FDA accepts Roche’s New Drug Application for Xofluza (baloxavir marboxil) for the treatment of influenza in children mehr
Published on: 25 März 2020 Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr
Published on: 23 März 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia mehr
Published on: 19 März 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia mehr
Published on: 16 März 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance mehr
Published on: 14 März 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended mehr
Published on: 13 März 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr
Published on: 12 März 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia mehr
Published on: 11 März 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention mehr
Published on: 4 März 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma mehr
Published on: 3 März 2020 FDA grants Breakthrough Therapy Designation for Roche’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease mehr
Published on: 25 Februar 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer mehr
Published on: 21 Februar 2020 Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer mehr
Published on: 19 Februar 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer mehr
Published on: 14 Februar 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer mehr
Published on: 11 Februar 2020 Reminder: Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr
Published on: 10 Februar 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease mehr
Published on: 7 Februar 2020 Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer mehr
Published on: 6 Februar 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy mehr
Published on: 31 Januar 2020 Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia mehr
Published on: 31 Januar 2020 Reminder: Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr
Published on: 27 Januar 2020 Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr
Published on: 27 Januar 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer mehr
Published on: 24 Januar 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer mehr
Published on: 23 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr
Published on: 23 Januar 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy mehr
Published on: 21 Januar 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma mehr
Published on: 17 Januar 2020 Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr
Published on: 13 Januar 2020 Roche and Illumina partner to broaden patient access to genomic testing mehr
Published on: 10 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr